News

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

- Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - Monotherapy arm has…

1 year ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases

Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa…

1 year ago

Emerging Markets Report: Smart Minds, Smart Money

Vinergy Developing and Investing in the Next Generation of A.I. Driven Health CareAn Emerging Markets Sponsored Commentary ORLANDO, Fla, Sept.…

1 year ago

Revolutionizing Surgical Training: CSurgeries Partners with Sheltowee Network for Expansive Relaunch

LOUISVILLE, Ky., Sept. 27, 2023 (GLOBE NEWSWIRE) -- via IBN - CSurgeries, a top-tier online surgical video journal, is proud…

1 year ago

Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician-Controlled Mobile App

Committed to progressing scalable AI technologies, Augmedix’s newest fully automated product is adaptable to serve acute and ambulatory care settingsSAN…

1 year ago

Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023

AUDUBON, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced…

1 year ago

Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining…

1 year ago

Sibannac, Inc. Signs Heads of Terms Agreement with Allstar Health-Tyme Cannabis to Enter the Canadian Cannabis Retail Market

Scottsdale, Arizona--(Newsfile Corp. - September 27, 2023) - Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the "Company"), announced the…

1 year ago

Therma Bright Announces Amendments to InStatin & InVixa Acquisitions

InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)Toronto, Ontario--(Newsfile Corp. - September…

1 year ago

Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial

Patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist Phase 1 study complete and data will…

1 year ago